Nilo Therapeutics launches with $101M — Columbia/Yale/Harvard scientists target brain-immune axis for autoimmune disease
Summary
Nilo Therapeutics emerged from stealth October 8, 2025 with $101M Series A led by The Column Group, DCVC Bio, and Lux Capital, with Gates Foundation and Alexandria Venture Investments. The company targets vagal neurons that regulate immune activation — based on Zuker (Columbia) Nature-published research. CEO Kim Seth (ex-Repare CBO). Targeting rheumatoid arthritis, IBD, lupus, and other autoimmune diseases via pharmacological vagal neural circuit modulation.
Why it matters
Lux Capital leading both Beacon Biosignals and Nilo Therapeutics in 2025-2026 signals that Lux has a clear neuro-immune/neuro-analytic thesis spanning drug development and data analytics. The Gates Foundation investing in a company that targets neural circuits for immune disease reflects their global health mandate — autoimmune and inflammatory diseases have enormous disease burden in low- and middle-income countries where biologics are unaffordable.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial